Hong In Yoon1, Ik Jae Lee, Kwang-Hyub Han, Jinsil Seong. 1. Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea.
Abstract
AIM: To investigate whether image-guided intensity-modulated radiation therapy (IG-IMRT) improves survival in hepatocellular carcinoma (HCC) relative to 3-dimensional conformal radiotherapy (3D-CRT). METHODS: Between 2006 and 2011, 187 HCC patients treated with definitive RT were reviewed. Median age was 53(range 51-83). All patients were stage III or IV-A. Concurrent chemoradiation was received by 178 patients (95.2 %). Overall actuarial survival (OS), progression-free survival (PFS), and infield-failure-free survival (IFFS) analyses were performed by Kaplan-Meier method. A Cox proportional hazards model was used for univariate and multivariate analysis. Pearson's chi-square test or Fisher's exact test was used to compare patient characteristics and treatment-related toxicity between the groups. RESULTS: Sixty-five patients were treated with IG-IMRT and 122 patients with 3D-CRT. No significant differences were seen between the groups for all patient characteristics. IG-IMRT delivered higher doses than 3D-CRT (median biological effective dose 62.5 vs 53.1 Gy, P < 0.001). IG-IMRT showed significantly higher 3-year OS (33.4 vs 13.5 %, P < 0.001), PFS (11.1 vs 6.0 %, P = 0.004), and IFFS (46.8 vs 28.2 %, P = 0.007) than 3D-CRT. On univariate and multivariate analysis, RT modality was significant prognostic factor for OS (HR 2.18; 95 % CI 1.45-3.25; P < 0.001), PFS (HR 1.64; 95 % CI 1.17-2.29; P = 0.004). There was no significant difference between the two modalities for radiation-induced liver disease (P = 0.716). CONCLUSION: Our findings suggest that IG-IMRT could be an effective treatment that provides survival benefit without increasing severe toxicity in locally advanced HCC.
AIM: To investigate whether image-guided intensity-modulated radiation therapy (IG-IMRT) improves survival in hepatocellular carcinoma (HCC) relative to 3-dimensional conformal radiotherapy (3D-CRT). METHODS: Between 2006 and 2011, 187 HCC patients treated with definitive RT were reviewed. Median age was 53(range 51-83). All patients were stage III or IV-A. Concurrent chemoradiation was received by 178 patients (95.2 %). Overall actuarial survival (OS), progression-free survival (PFS), and infield-failure-free survival (IFFS) analyses were performed by Kaplan-Meier method. A Cox proportional hazards model was used for univariate and multivariate analysis. Pearson's chi-square test or Fisher's exact test was used to compare patient characteristics and treatment-related toxicity between the groups. RESULTS: Sixty-five patients were treated with IG-IMRT and 122 patients with 3D-CRT. No significant differences were seen between the groups for all patient characteristics. IG-IMRT delivered higher doses than 3D-CRT (median biological effective dose 62.5 vs 53.1 Gy, P < 0.001). IG-IMRT showed significantly higher 3-year OS (33.4 vs 13.5 %, P < 0.001), PFS (11.1 vs 6.0 %, P = 0.004), and IFFS (46.8 vs 28.2 %, P = 0.007) than 3D-CRT. On univariate and multivariate analysis, RT modality was significant prognostic factor for OS (HR 2.18; 95 % CI 1.45-3.25; P < 0.001), PFS (HR 1.64; 95 % CI 1.17-2.29; P = 0.004). There was no significant difference between the two modalities for radiation-induced liver disease (P = 0.716). CONCLUSION: Our findings suggest that IG-IMRT could be an effective treatment that provides survival benefit without increasing severe toxicity in locally advanced HCC.
Authors: Charlie C Pan; Brian D Kavanagh; Laura A Dawson; X Allen Li; Shiva K Das; Moyed Miften; Randall K Ten Haken Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: T R Mackie; T Holmes; S Swerdloff; P Reckwerdt; J O Deasy; J Yang; B Paliwal; T Kinsella Journal: Med Phys Date: 1993 Nov-Dec Impact factor: 4.071
Authors: Sang Min Yoon; Young-Suk Lim; Hyung Jin Won; Jong Hoon Kim; Kang Mo Kim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee; Sung Gyu Lee; Jin-Hong Park; Dong Jin Suh Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-27 Impact factor: 7.038
Authors: Alejandra Méndez Romero; Wouter Wunderink; Shahid M Hussain; Jacco A De Pooter; Ben J M Heijmen; Peter C J M Nowak; Joost J Nuyttens; Rene P Brandwijk; Cees Verhoef; Jan N M Ijzermans; Peter C Levendag Journal: Acta Oncol Date: 2006 Impact factor: 4.089
Authors: Hong In Yoon; Ki Jun Song; Ik Jae Lee; Do Young Kim; Kwang-Hyub Han; Jinsil Seong Journal: Cancer Res Treat Date: 2015-03-05 Impact factor: 4.679
Authors: Hyejung Cha; Hee Chul Park; Jeong Il Yu; Tae Hyun Kim; Taek-Keun Nam; Sang Min Yoon; Won Sup Yoon; Jun Won Kim; Mi Sook Kim; Hong Seok Jang; Youngmin Choi; Jin Hee Kim; Chul Seung Kay; Inkyung Jung; Jinsil Seong Journal: Cancer Res Treat Date: 2016-06-13 Impact factor: 4.679